Dosen af ViraferonPeg i monoterapi bør reduceres hos patienter med moderat eller kraftigt nedsat nyrefunktion (se pkt.
113 ViraferonPeg for monotherapy should be reduced in patients with moderate or severe renal impairment (see sections 4.2 and 4.4).